Overview
A Safety Study of Combination Treatment With Avonex and Placebo-Controlled Dosing of Topamax in Relapsing-Remitting Multiple Sclerosis
Status:
Unknown status
Unknown status
Trial end date:
2007-12-01
2007-12-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This is a clinical trial in relapsing-remitting Multiple Sclerosis to determine if Topamax added to Avonex has a neuroprotective effect as measured by the brain parenchymal fraction ( a measure of brain shrinkage) and by clinical assessment scores to evaluate disease progression.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Multiple Sclerosis InstituteTreatments:
Interferon beta-1a
Topiramate
Criteria
Inclusion Criteria:Relapsing-remitting multiple sclerosis
-
Exclusion Criteria:
Secondary progressive multiple sclerosis Contraindication to MRI Systemic disease Pregnancy
-